New England Journal of Medicine (New Engl J Med)

Publisher: Massachusetts Medical Society, Massachusetts Medical Society

Journal description

One of the world's leading medical journals, the NEJM publishes original research and interpretive articles in major aspects of medicine: its science, its art and practice, and its position in today's society. Each week, The Journal presents major, previously unpublished research results, clinical findings, updates and opinions.

Current impact factor: 55.87

Impact Factor Rankings

2016 Impact Factor Available summer 2017
2014 / 2015 Impact Factor 55.873
2013 Impact Factor 54.42
2012 Impact Factor 51.658
2011 Impact Factor 53.298
2010 Impact Factor 53.484
2009 Impact Factor 47.05
2008 Impact Factor 50.017
2007 Impact Factor 52.589
2006 Impact Factor 51.296
2005 Impact Factor 44.016
2004 Impact Factor 38.57
2003 Impact Factor 34.833
2002 Impact Factor 31.736
2001 Impact Factor 29.065
2000 Impact Factor 29.512
1999 Impact Factor 28.857
1998 Impact Factor 28.66
1997 Impact Factor 27.766
1996 Impact Factor 24.834
1995 Impact Factor 22.412
1994 Impact Factor 22.673
1993 Impact Factor 23.762
1992 Impact Factor 24.455

Impact factor over time

Impact factor
Year

Additional details

5-year impact 54.39
Cited half-life 8.40
Immediacy index 13.84
Eigenfactor 0.68
Article influence 24.26
Website New England Journal of Medicine website
Other titles New England journal of medicine (Online), New England journal of medicine, NEJM
ISSN 1533-4406
OCLC 34945333
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Massachusetts Medical Society

  • Pre-print
    • Author cannot archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Conditions
    • Publisher's version/PDF must be used
    • Publisher copyright and source must be acknowledged
    • On non-profit open access repository, including institutional repository
    • NIH and Wellcome Trust authors will have their published article deposited in PubMed Central on their behalf after 6 months embargo
    • Publisher last reviewed on 09/07/2015
  • Classification
    white

Publications in this journal

  • [Show abstract] [Hide abstract] ABSTRACT: A 78-year-old woman who had undergone coronary aortic bypass surgery 30 years earlier presented to the ED with shortness of breath and fatigue. Chest radiography revealed a mediastinal, hilar mass lesion on the left side.
    No preview · Article · Apr 2016 · New England Journal of Medicine
  • [Show abstract] [Hide abstract] ABSTRACT: Violence against health care professionals in the workplace is underreported and understudied. Additional data are needed to understand steps that might be taken to reduce the risk.
    No preview · Article · Apr 2016 · New England Journal of Medicine
  • [Show abstract] [Hide abstract] ABSTRACT: A 49-year-old woman was brought to the ED 2 hours after the onset of hemiplegia and aphasia during a transatlantic flight. Examination revealed evidence of acute ischemic stroke. Additional diagnostic studies were performed.
    No preview · Article · Apr 2016 · New England Journal of Medicine
  • [Show abstract] [Hide abstract] ABSTRACT: From a low-income country like Malawi, it can be difficult to appreciate the tangible fruits of a decades-long international war on cancer. Shooting for the moon in cancer science is important, but so is shooting for a world that is just and equitable.
    No preview · Article · Apr 2016 · New England Journal of Medicine
  • [Show abstract] [Hide abstract] ABSTRACT: To the Editor: Reinöhl et al. (Dec. 17 issue)(1) report on the numbers of surgical aortic-valve replacement and transcatheter aortic-valve replacement (TAVR) procedures performed in Germany between 2007 and 2013. We are concerned about the validity of using the German Diagnosis Related Groups (G-DRG)-based data source. More reliable databases are available. In particular, the mandatory external quality-assurance database (the AQUA Quality Report) is considered to be nearly complete and therefore most representative of the German experience with TAVR and surgical aortic-valve replacement.(2)-(4) There is a major discrepancy between the numbers of procedures reported by Reinöhl et al. and the . . .
    No preview · Article · Apr 2016 · New England Journal of Medicine
  • [Show abstract] [Hide abstract] ABSTRACT: A 49-year-old woman without a personal or family history of melanoma presented with an asymptomatic pigmented lesion on her tongue that was suggestive of oral melanoma. The patient reported that she had undergone a dental procedure 3 months before the appearance of the lesion.
    No preview · Article · Apr 2016 · New England Journal of Medicine
  • [Show abstract] [Hide abstract] ABSTRACT: To the Editor: Romani et al. report the efficacy of mass treatment with oral ivermectin in an island community with hyperendemic scabies (Dec. 10 issue).(1) I would like to discuss a point that, unlike the authors, I found likely to be expected - that is, the persistent and major decline in scabies prevalence observed with that protocol. Indeed, although oral ivermectin appears slightly less efficacious in the treatment of individual cases of scabies than topical compounds such as permethrin or benzyl benzoate,(2) it is considered to bring a major advantage during mass treatment of epidemics in closed communities such as . . .
    No preview · Article · Apr 2016 · New England Journal of Medicine
  • [Show abstract] [Hide abstract] ABSTRACT: To the Editor: Romani et al. report the efficacy of mass treatment with oral ivermectin in an island community with hyperendemic scabies (Dec. 10 issue).(1) I would like to discuss a point that, unlike the authors, I found likely to be expected - that is, the persistent and major decline in scabies prevalence observed with that protocol. Indeed, although oral ivermectin appears slightly less efficacious in the treatment of individual cases of scabies than topical compounds such as permethrin or benzyl benzoate,(2) it is considered to bring a major advantage during mass treatment of epidemics in closed communities such as . . .
    No preview · Article · Apr 2016 · New England Journal of Medicine
  • [Show abstract] [Hide abstract] ABSTRACT: To the Editor: Foster et al. (Dec. 31 issue)(1) report on the results of the ASTRAL-3 trial. Rates of sustained virologic response at 12 weeks after the end of therapy with sofosbuvir-velpatasvir for hepatitis C virus (HCV) genotype 3 infection were 93% among patients with cirrhosis who had not received prior treatment and 89% among patients with cirrhosis who had received prior treatment. However, in the ASTRAL-4 trial reported by Curry et al. in the same issue of the Journal,(2) rates of sustained virologic response at 12 weeks with sofosbuvir-velpatasvir were only 50% among patients with genotype 3 infection and . . .
    No preview · Article · Apr 2016 · New England Journal of Medicine
  • [Show abstract] [Hide abstract] ABSTRACT: Duchenne's muscular dystrophy is caused by a loss-of-function mutation in DMD. Studies of the CRISPR-Cas9 method of excising the mutated region show efficacy in a mouse model of the disease.
    No preview · Article · Apr 2016 · New England Journal of Medicine
  • [Show abstract] [Hide abstract] ABSTRACT: U.S. colorectal-cancer incidence has dropped by more than 45% since its peak in the mid-1980s, and related mortality has fallen by more than half. But though screening is often credited for these trends, it cannot explain such large decreases.
    No preview · Article · Apr 2016 · New England Journal of Medicine
  • [Show abstract] [Hide abstract] ABSTRACT: To the Editor: Blinderman and Billings (Dec. 24 issue)(1) summarize "guidelines for physicians in discussing values . . . with patients near the end of life." I often observe a lack of objectivity on the part of caregivers because differing values are not respected. A decision by a patient or family member to have life extended, with some degree of suffering, is subject to a value system in which quality of life is weighed against quantity of life. It is natural that many clinicians in the field of palliative care have their own values. Caregivers must be trained to respect the values of patients . . .
    No preview · Article · Apr 2016 · New England Journal of Medicine
  • [Show abstract] [Hide abstract] ABSTRACT: To the Editor: Reinöhl et al. (Dec. 17 issue)(1) report on the numbers of surgical aortic-valve replacement and transcatheter aortic-valve replacement (TAVR) procedures performed in Germany between 2007 and 2013. We are concerned about the validity of using the German Diagnosis Related Groups (G-DRG)-based data source. More reliable databases are available. In particular, the mandatory external quality-assurance database (the AQUA Quality Report) is considered to be nearly complete and therefore most representative of the German experience with TAVR and surgical aortic-valve replacement.(2)-(4) There is a major discrepancy between the numbers of procedures reported by Reinöhl et al. and the . . .
    No preview · Article · Apr 2016 · New England Journal of Medicine
  • [Show abstract] [Hide abstract] ABSTRACT: When children need medical care, the situation can be stressful for both the parents and the child. This video describes the signs of acute anxiety in children and demonstrates approaches to interacting with children that minimize anxiety and maximize cooperation.
    No preview · Article · Apr 2016 · New England Journal of Medicine
  • [Show abstract] [Hide abstract] ABSTRACT: To the Editor: It is not surprising that Burger et al. (Dec. 17 issue)(1) report positive results in the Study of Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia (RESONATE-2), a randomized trial of ibrutinib versus chlorambucil in older patients with chronic lymphocytic leukemia (CLL). Chlorambucil has served as a comparator in trials of bendamustine, alemtuzumab, ofatumumab, and obinutuzumab, and longer durations of progression-free survival have been reported with each agent.(2)-(5) In addition, these trials have shown longer durations of overall survival with the use of ibrutinib and obinutuzumab.(1),(2) We reviewed our experience in the Connect . . .
    No preview · Article · Apr 2016 · New England Journal of Medicine
  • [Show abstract] [Hide abstract] ABSTRACT: To the Editor: Makkar et al. (Nov. 19 issue)(1) report possible subclinical leaflet thrombosis in up to 40% of patients involved in a clinical trial of transcatheter aortic-valve replacement (TAVR). In contrast, we found a relatively low incidence (7%) of possible subclinical valve leaflet thrombosis among patients in our series in which 255 patients underwent TAVR with the use of a CoreValve prosthesis. A retrospective review of our series (unpublished data) showed that in 104 patients, cardiac computed tomography (CT) at a median of 7 days after implantation (range, 3 to 87) (in 51 patients), transesophageal echocardiography at a median . . .
    No preview · Article · Apr 2016 · New England Journal of Medicine
  • [Show abstract] [Hide abstract] ABSTRACT: To the Editor: Makkar et al. (Nov. 19 issue)(1) report possible subclinical leaflet thrombosis in up to 40% of patients involved in a clinical trial of transcatheter aortic-valve replacement (TAVR). In contrast, we found a relatively low incidence (7%) of possible subclinical valve leaflet thrombosis among patients in our series in which 255 patients underwent TAVR with the use of a CoreValve prosthesis. A retrospective review of our series (unpublished data) showed that in 104 patients, cardiac computed tomography (CT) at a median of 7 days after implantation (range, 3 to 87) (in 51 patients), transesophageal echocardiography at a median . . .
    No preview · Article · Apr 2016 · New England Journal of Medicine
  • [Show abstract] [Hide abstract] ABSTRACT: To the Editor: In their article on the Nitrate's Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction (NEAT-HFpEF) trial, Redfield et al. (Dec. 10 issue)(1) show a significant linear relationship between the dose of isosorbide mononitrate and daily physical activity quantified by means of accelerometers. They interpret the findings to indicate an adverse effect of isosorbide mononitrate in patients with heart failure and a preserved ejection fraction. We favor a different view - that the use of isosorbide mononitrate at a dose of up to 120 mg per day caused subtle but disabling symptoms such as headache, . . .
    No preview · Article · Apr 2016 · New England Journal of Medicine